BiotechTube

MAT2203 + Amphotericin B

Phase 3UNKNOWN
0 views this week 0 watching💤 Quiet
Interest: 26/100
26
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
✓
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Cryptococcal Meningitis

Conditions

Cryptococcal Meningitis

Trial Timeline

Jan 1, 2023 → Jan 1, 2025

NCT ID
NCT05541107

About MAT2203 + Amphotericin B

MAT2203 + Amphotericin B is a phase 3 stage product being developed by Matinas Biopharma for Cryptococcal Meningitis. The current trial status is unknown. This product is registered under clinical trial identifier NCT05541107. Target conditions include Cryptococcal Meningitis.

What happened to similar drugs?

0 of 1 similar drugs in Cryptococcal Meningitis were approved

Approved (0) Terminated (0) Active (1)
🔄Fluconazole + Amphotericin BPfizerPhase 3

Hype Score Breakdown

Clinical
17
Activity
4
Company
5
Novelty
0
Community
0

Clinical Trials (2)

NCT IDPhaseStatus
NCT05541107Phase 3UNKNOWN
NCT04031833Phase 1/2Completed

Competing Products

18 competing products in Cryptococcal Meningitis

See all competitors
ProductCompanyStageHype Score
Efungumab (Mycograb) + placebo + Amphotericin B + 5 flucytosineNovartisPhase 2
27
Mycograb + placeboNovartisPhase 2
27
Single dose liposomal Amphotericin and Fluconazole + FluconazoleGilead SciencesPhase 2/3
45
FluconazolePfizerPre-clinical
26
FluconazolePfizerPre-clinical
26
Fluconazole + Amphotericin BPfizerPre-clinical
26
Flucytosine + FluconazolePfizerPre-clinical
26
Fluconazole + Amphotericin BPfizerPre-clinical
26
Flucytosine + Fluconazole + Amphotericin BPfizerPre-clinical
26
FluconazolePfizerPre-clinical
26
FluconazolePfizerPre-clinical
26
Fluconazole + Amphotericin BPfizerPhase 3
40
Flucytosine + Fluconazole + Amphotericin BPfizerPre-clinical
26
FluconazolePfizerPre-clinical
26
Lobradimil + Amphotericin BAlkermesPhase 1
26
Flucytosine and fluconazole + FluconazoleBausch HealthPhase 2
21
MAT2203 + Amphotericin BMatinas BiopharmaPhase 1/2
22
Encochleated Amphotericin BMatinas BiopharmaPhase 1/2
14